Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 148
Filtrer
2.
Pediatr Dermatol ; 40(3): 440-445, 2023.
Article de Anglais | MEDLINE | ID: mdl-36716766

RÉSUMÉ

BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a locally aggressive and potentially lethal vascular tumor of infancy. Current consensus recommendations include the use of vincristine and/or systemic steroids as first-line treatment. Mammalian target of rapamycin (mTOR) inhibitors represent a promising therapy for patients with KHE. The goal of our study is to critically assess the existing literature on outcomes of patients with KHE treated with mTOR inhibitors. METHODS: We conducted a literature search from 1 January 2000, to 30 April 2022. Articles reporting outcomes of patients treated with mTOR inhibitors for KHE were included. Descriptive statistics were used to describe and summarize the outcomes of the treatment. RESULTS: We included 327 patients with a mean age at diagnosis of 9.1 months (SD ± 9). Patients were treated with an mTOR inhibitor for a mean of 15.2 months (SD ± 4.1). A total of 315 (96.3%) patients had positive outcomes including improvement of the tumor size, symptoms and/or laboratory parameters in 227 (85%) and complete remission in 38 (12%). Seven (2%) patients did not respond to treatment and seven (2%) died of sepsis (4), Kasabach-Merritt phenomenon complications (1), cardiac and liver failure due to ductus arteriosus (1), or metastatic disease (1). CONCLUSION: This systematic review supports the efficacy and safety of mTOR inhibitors for KHE. Their use resulted in positive outcomes in terms of decreased symptoms, reduction in tumor size and improvement in biochemical parameters with a mortality rate of 2%. According to these findings, we suggest revised consensus treatment guidelines for KHE with mTOR inhibitors potentially considered first-line therapy.


Sujet(s)
Hémangioendothéliome , Syndrome de Kasabach-Merritt , Sarcome de Kaposi , Humains , Nourrisson , Syndrome de Kasabach-Merritt/diagnostic , Sirolimus/usage thérapeutique , Inhibiteurs de mTOR , Hémangioendothéliome/diagnostic , Sarcome de Kaposi/complications , Sérine-thréonine kinases TOR/usage thérapeutique
3.
J Foot Ankle Surg ; 62(3): 458-464, 2023.
Article de Anglais | MEDLINE | ID: mdl-36496339

RÉSUMÉ

Intravascular endothelial hyperplasia is a benign soft tissue mass rarely reported in the foot. Advanced imaging and confirming a benign diagnosis are critical for any soft tissue mass. This paper identifies 2 patients that developed intravascular endothelial hyperplasia tumors which required surgical excision. A 17-year-old male patient presented to clinic complaining of a painful bump to the arch of his right foot which he related to an injury 9 months prior. Magnetic resonance imaging of the right foot revealed a mass within the plantar subcutaneous fat that was serpiginous in nature similar to adjacent branching vessels favoring a low-flow vascular malformation. A 38-year-old female with Multiple Sclerosis presented with complaints of persistent symptoms of pain to the 1st interspace, difficult ambulation and neuritis. Ultrasound and MRI observed solid, multilobulated mass, with internal vascular malformation, MRI describing intrinsic involvement along the abductor musculature and flexor tendons. Both lesions were surgically excised and sent for pathology. Pathology report indicated a diagnosis of intravascular papillary endothelial hyperplasia or Masson's tumor in both cases. Pathology diagnosis of intravascular papillary endothelial hyperplasia is generally good with wide resection leading to low recurrence rates. Both patients in the current study have progressed postoperatively with resolution of symptoms and without recurrence.


Sujet(s)
Hémangioendothéliome , Anomalies vasculaires , Tumeurs vasculaires , Mâle , Femelle , Humains , Adulte , Adolescent , Hémangioendothéliome/imagerie diagnostique , Hémangioendothéliome/chirurgie , Hyperplasie/chirurgie , Hyperplasie/anatomopathologie , Pied/imagerie diagnostique , Pied/chirurgie , Pied/anatomopathologie , Tumeurs vasculaires/anatomopathologie , Anomalies vasculaires/diagnostic , Anomalies vasculaires/anatomopathologie , Diagnostic différentiel
5.
Arch Osteoporos ; 17(1): 28, 2022 02 01.
Article de Anglais | MEDLINE | ID: mdl-35106633

RÉSUMÉ

Pseudomyogenic hemangioendothelioma (PMH) can be a challenge for diagnosis and might be confused with other tumors, such as epithelioid sarcoma. Here we present a case and a systematic review of the literature to identify and discuss PMH treatment in primary bone involvement. A 25-year-old woman was referred for bone pain (10/10) in the left lower limb. Magnetic resonance imaging (MRI) showed multiple bone lesions (left femur, tibia, patella, ankle, and foot) with well-defined borders without signs of local aggressiveness. Positron Emission Tomography-Computed Tomography (PET-CT) showed multiple metabolic musculoskeletal lesions in the left lower limb. A CT scan-guided biopsy was performed. Histological and immunohistochemical findings confirmed the diagnosis of PMH. After treatment with intravenous pamidronate (90 mg/monthly), the patient had clinical improvement, mild pain 2/10 without the use of non-steroidal anti-inflammatory drugs or opiates. Follow-up was assessed by MRI and PET-CT. PET-CT showed metabolic resolution of most of the bone and muscular lesions and a significant improvement of the femoral lesion. MRI showed that the lesions in the left femur, tibia, and foot had a marked decrease in size without intravenous post-contrast enhancement and smaller lesions had disappeared. After a 3-year follow-up, PET-CT showed no metabolically active images. Literature review identified 31 records including 58 clinical cases of PMH with primary bone involvement and treatment description for qualitative analysis. Most lesions (69%) were treated by local excision or curettage. In addition, amputations were performed in a significant percentage of cases (20.7%). In the last years, mTOR inhibitors (n = 7) and anti-resorptive treatments (n = 4) were considered as alternative treatment options, especially in multifocal lesions.


Sujet(s)
Hémangioendothéliome , Tomographie par émission de positons couplée à la tomodensitométrie , Adulte , Os et tissu osseux/anatomopathologie , Femelle , Hémangioendothéliome/anatomopathologie , Hémangioendothéliome/chirurgie , Humains , Imagerie par résonance magnétique , Pamidronate/usage thérapeutique
7.
Bol Med Hosp Infant Mex ; 78(4): 376-384, 2021.
Article de Espagnol | MEDLINE | ID: mdl-34351887

RÉSUMÉ

INTRODUCCIÓN: El hemangioendotelioma kaposiforme (HEK) es un tumor vascular poco frecuente caracterizado por una invasión local agresiva y un síndrome de atrapamiento de plaquetas conocido como fenómeno de Kasabach-Merritt. Aunque muchos casos de HEK se tratan con éxito con control local o quimioterapia de baja intensidad, otros son resistentes y se cuenta con pocas opciones terapéuticas. El objetivo de este reporte es mostrar la experiencia del tratamiento con sirolimus por vía oral en un paciente pediátrico con HEK asociado a fenómeno de Kasabach-Merritt refractario al tratamiento de primera línea, quien mostró excelente respuesta al tratamiento. CASO CLÍNICO: Paciente de sexo masculino de 3 meses con un HEK refractario al manejo de primera línea (corticoides, propranolol, vincristina), sin posibilidad de hacer control local, por lo que se decide terapia combinada con sirolimus, presentando control local y resolución de la coagulopatía desde la primera semana de iniciado el manejo y con resolución de la malformación vascular después de 12 meses de seguimiento. CONCLUSIONES: Aunque no existen pautas claras para el tratamiento del HEK refractario en la edad pediátrica, la evidencia actual demuestra que el sirolimus es un medicamento eficaz que puede ser considerado como opción terapéutica de primera línea en estos pacientes. BACKGROUND: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor characterized by aggressive local invasion and a platelet entrapment syndrome known as the Kasabach-Merritt phenomenon. Although many cases of KHE are successfully treated with local control or low-intensity chemotherapy, some cases are often resistant, with few therapeutic options available. Here, we report a pediatric patient with KHE associated with Kasabach-Merritt phenomenon refractory to first-line treatment, who demonstrated excellent response to treatment. CASE REPORT: We present the case of a 3-month-old male patient with a KHE refractory to first-line treatment (vincristine, corticosteroids, propranolol), without possibility of local control treatment. Therefore, combined therapy with sirolimus was decided, presenting local control and resolution of the coagulopathy from the first week after starting the management and with resolution of vascular malformation after 12 months of ­follow-up. CONCLUSIONS: Although there are no clear guidelines for the treatment of refractory KHE in the pediatric population, current evidence demonstrate that sirolimus is an effective option that could be considered as a first-line treatment in such patients.


Sujet(s)
Hémangioendothéliome , Syndrome de Kasabach-Merritt , Sarcome de Kaposi , Enfant , Hémangioendothéliome/diagnostic , Hémangioendothéliome/traitement médicamenteux , Humains , Nourrisson , Syndrome de Kasabach-Merritt/diagnostic , Syndrome de Kasabach-Merritt/traitement médicamenteux , Mâle
8.
Head Neck Pathol ; 15(4): 1421-1425, 2021 Dec.
Article de Anglais | MEDLINE | ID: mdl-33715098

RÉSUMÉ

Kaposiform hemangioendothelioma is a rare neoplasm with intermediate malignant behavior, mainly affecting infants and children. Involvement head and neck is uncommon, and there are only four cases reported in the oral cavity and oropharynx. Microscopically, it is characterized by a vascular proliferation permeated by spindle-to-ovoid cells resembling Kaposi sarcoma. Immunohistochemically, the tumor is positive for CD31, CD34 and negative for D2-40. Herein we present a rare case of intraoral Kaposiform hemangioendothelioma in a 10-year-old boy.


Sujet(s)
Hémangioendothéliome/diagnostic , Syndrome de Kasabach-Merritt/diagnostic , Tumeurs de la bouche/diagnostic , Sarcome de Kaposi/diagnostic , Marqueurs biologiques tumoraux/analyse , Enfant , Diagnostic différentiel , Hémangioendothéliome/anatomopathologie , Hémangioendothéliome/chirurgie , Humains , Syndrome de Kasabach-Merritt/anatomopathologie , Syndrome de Kasabach-Merritt/chirurgie , Mâle , Tumeurs de la bouche/anatomopathologie , Tumeurs de la bouche/chirurgie , Radiographie panoramique , Sarcome de Kaposi/anatomopathologie , Sarcome de Kaposi/chirurgie
9.
J Oral Pathol Med ; 50(1): 103-113, 2021 Jan.
Article de Anglais | MEDLINE | ID: mdl-33188642

RÉSUMÉ

BACKGROUND: Intravascular papillary endothelial hyperplasia is an unusual vascular lesion characterized by the proliferation of endothelial cells. The aim of this study was to determine the frequency and general features of this lesion. METHODS: Biopsy records of three oral pathology services were reviewed for intravascular papillary endothelial hyperplasia cases from 1959 to 2020. In addition, a systematic review of case reports and case series was carried out in eight electronic databases. RESULTS: Of the 65 205 retrieved cases, 20 (0.03%) were diagnosed as intravascular papillary endothelial hyperplasia. Mean patient age was 46.55 years, and females (12 cases/60%) were more affected. The lower lip (9 cases/47.36%) was the most commonly affected site, and the lesions were generally asymptomatic (7 cases/63.63%). Clinically, 90% of the lesions presented (18 cases) as a nodule, with a mean size of 1.13 cm. The clinical diagnostic hypotheses most frequently raised were mucocele (6 cases/37.50%) and hemangioma (5 cases/31.25%). An excisional biopsy was chosen in all cases for treatment. Forty-nine studies of the systematic review were included, yielding 105 cases. The literature showed similarity in all variables. CONCLUSION: Despite the uncommon frequency, clinicians and oral pathologists should familiarize themselves with the similarities between intravascular papillary endothelial hyperplasia and some other lesions in terms of clinical and histological features.


Sujet(s)
Hémangioendothéliome , Muqueuse de la bouche , Diagnostic différentiel , Cellules endothéliales , Endothélium vasculaire/anatomopathologie , Femelle , Hémangioendothéliome/diagnostic , Hémangioendothéliome/anatomopathologie , Humains , Hyperplasie/anatomopathologie , Adulte d'âge moyen
10.
Int. j. morphol ; 38(4): 1060-1064, Aug. 2020. graf
Article de Espagnol | LILACS | ID: biblio-1124897

RÉSUMÉ

La linfangiomatosis es una patología benigna, de etiología desconocida, que afecta especialmente a población pediátrica, caracterizándose por desarrollo de masas subcutáneas que involucran uno o más órganos. Cuando se asocia con coagulopatía y derrames quilosos, recibe el nombre de linfangiomatosis kaposiforme (LK), cuya evidencia disponible es escasa. El objetivo de este manuscrito es reportar un caso de LK pediátrico atendido en el Instituto del Cáncer SOLCA, Cuenca, Ecuador. Paciente femenina de 1 año 7 meses, con hernia inguinal bilaterales y alteración de los tiempos de coagulación. En los estudios de imagen se evidenció una masa mediastínica asociada a presencia de líquido en espacio pleural y cavidad abdomino-pélvica. Además, se evidenció la existencia de múltiples imágenes hipogénicas en el bazo. Se practicó timectomía mínima, toma de biopsia de linfonodos mediastínicos para establecer el diagnóstico, y se instaló un dren en el tórax para tratar el derrame pleural antes señalado. Se descartaron patologías similares (linfomas, lupus, inmunológicas, etc.). Dado el continúo deterioro respiratorio, coagulopatía, lesiones hipogénicas esplénicas y drenaje abundante del quilotórax por el tubo torácico, se planteó el diagnóstico de LK. Se inició apoyo nutricional vía parenteral (sin lípidos); se indicó vincristina, y se realizó una pleurodesis con bleomicina sin buena respuesta. La paciente falleció a los 16 días de su ingreso. Se trata de un caso de mal pronóstico, con evolución rápidamente progresiva hacia un desenlace fatal.


Lymphangiomatosis is a benign pathology, of unknown etiology. Affects especially to pediatric population and is characterized by development of subcutaneous masses that involve one or more organs. When it presents with coagulopathy and chylous effusions, it is called kaposiform lymphangiomatosis (KL). The available evidence of KL is scarce. The objective of this manuscript was to report a case of pediatric KL treated at SOLCA Cancer Institute, Cuenca, Ecuador. Female patient of 1 year and 7 months age. She had a bilateral inguinal hernia and altered coagulation times. Imaging studies revealed a mediastinal mass associated with fluid in the pleural space and in the abdominalpelvic cavity. Furthermore, the existence of multiple hypogenic images in the spleen was evidenced. Minimal thymectomy, biopsy of mediastinal lymph nodes was performed to establish the diagnosis, and a drain was installed in the chest to treat the aforementioned pleural effusion. Other pathologies like lymphomas, lupus, etc. were ruled out. Given the continuous respiratory deterioration, coagulopathy, splenic hypogenic lesions and abundant drainage of the chylothorax through the chest tube, the diagnosis of KL was raised. Parenteral nutrition (lipid-free) was started; Vincristine was indicated, and a pleurodesis with bleomycin was performed without a good response. The patient died 16 days after her admission. It is a case of very bad prognosis, with a rapidly progressive evolution towards a fatal outcome.


Sujet(s)
Humains , Nourrisson , Sarcome de Kaposi/imagerie diagnostique , Syndrome de Kasabach-Merritt/imagerie diagnostique , Hémangioendothéliome/imagerie diagnostique , Radiographie thoracique , Tomodensitométrie , Échographie , Issue fatale
11.
Ann Hepatol ; 19(5): 530-534, 2020.
Article de Anglais | MEDLINE | ID: mdl-32532590

RÉSUMÉ

INTRODUCTION AND OBJECTIVES: Infantile hepatic hemangioendothelioma (IHHE) is a benign liver tumor, associated with hypothyroidism and vascular malformations along the skin, brain, digestive tract and other organs. Here, we determined a single-center patient cohort by evaluating the effectiveness and safety of propranolol and sirolimus for the treatment of IHHE. PATIENTS AND METHODS: We performed a monocentric and observational study, based on clinical data obtained from 20 cases of IHHE treated with oral propranolol and sirolimus at the Shanghai Children's Medical Center (SCMC), between December 2017 and April 2019. All cases were confirmed by abdominal enhanced CT examination (18/20, 90%) and sustained decrease of alpha fetoprotein (AFP) (2/20, 10%). Propranolol treatment was standardized as once a day at 1.0mg/kg for patients younger than 2 months, and twice a day at 1.0mg/kg (per dose) for patients older than 2 months. Sirolimus was used to treat refractory IHHE patients after 6 months of propranolol treatment, and initial dosing was at 0.8mg/m2 body surface per dose, administered every 12h. Upon treatment, abdominal ultrasound scanning was regularly performed to evaluate any therapeutic effects. All children were followed up for 6-22 months (mean value of 12.75 months). The clinical manifestations and therapeutic effects, including complications during drug management, were reviewed after periodic follow-up. RESULTS: The effective rate of propranolol for the treatment of children with IHHE was 85% (17/20). In most cases, the AFP levels gradually decreased into the normal range. A complete response (CR) was achieved in 3 cases, partial response (PR) for 14 cases, progressive disease (PD) for 2 cases and stable disease (SD) was only detected once. Lesions decreased in two PD patients after administration of oral sirolimus. No serious adverse reactions were observed. CONCLUSION: This study indicates that both propranolol and sirolimus were effective drugs for the treatment of children with IHHE at SCMC.


Sujet(s)
Antinéoplasiques/administration et posologie , Hémangioendothéliome/traitement médicamenteux , Tumeurs du foie/traitement médicamenteux , Propranolol/administration et posologie , Sirolimus/administration et posologie , Administration par voie orale , Antinéoplasiques/effets indésirables , Enfant d'âge préscolaire , Chine , Femelle , Hémangioendothéliome/sang , Hémangioendothéliome/imagerie diagnostique , Hémangioendothéliome/anatomopathologie , Humains , Nourrisson , Nouveau-né , Tumeurs du foie/sang , Tumeurs du foie/imagerie diagnostique , Tumeurs du foie/anatomopathologie , Mâle , Propranolol/effets indésirables , Sirolimus/effets indésirables , Facteurs temps , Résultat thérapeutique , Alphafoetoprotéines/métabolisme
13.
An Bras Dermatol ; 95(2): 214-216, 2020.
Article de Anglais | MEDLINE | ID: mdl-32151408

RÉSUMÉ

Papillary intralymphatic angioendothelioma (Dabska tumor) is a rarely metastasizing lymphatic vascular neoplasm that usually affects children and young adults. The majority of these cases occur in soft tissues of extremities, and to date less than 40 cases have been described. Despite the generally indolent evolution, can be locally invasive with the potential to metastasize. We describe a case of a young woman presenting with a plantar lesion, for 9 months and histological diagnosis of Dabska tumor. This neoplasm should be considered in the differential diagnosis of vascular dermatoses, allowing early diagnosis and treatment. Long-term follow-up should be performed.


Sujet(s)
Maladies du pied/anatomopathologie , Hémangioendothéliome/anatomopathologie , Tumeurs des vaisseaux lymphatiques/anatomopathologie , Adulte , Biopsie , Dermoscopie , Diagnostic différentiel , Femelle , Maladies du pied/diagnostic , Hémangioendothéliome/diagnostic , Humains , Tumeurs des vaisseaux lymphatiques/diagnostic , Tumeurs cutanées/diagnostic , Tumeurs cutanées/anatomopathologie
14.
An. bras. dermatol ; An. bras. dermatol;95(2): 214-216, Mar.-Apr. 2020. graf
Article de Anglais | LILACS, Coleciona SUS | ID: biblio-1130843

RÉSUMÉ

Abstract Papillary intralymphatic angioendothelioma (Dabska tumor) is a rarely metastasizing lymphatic vascular neoplasm that usually affects children and young adults. The majority of these cases occur in soft tissues of extremities, and to date less than 40 cases have been described. Despite the generally indolent evolution, can be locally invasive with the potential to metastasize. We describe a case of a young woman presenting with a plantar lesion, for 9 months and histological diagnosis of Dabska tumor. This neoplasm should be considered in the differential diagnosis of vascular dermatoses, allowing early diagnosis and treatment. Long-term follow-up should be performed.


Sujet(s)
Humains , Femelle , Adulte , Tumeurs des vaisseaux lymphatiques/anatomopathologie , Maladies du pied/anatomopathologie , Hémangioendothéliome/anatomopathologie , Tumeurs cutanées/diagnostic , Tumeurs cutanées/anatomopathologie , Biopsie , Tumeurs des vaisseaux lymphatiques/diagnostic , Dermoscopie , Diagnostic différentiel , Maladies du pied/diagnostic , Hémangioendothéliome/diagnostic
15.
Rev Med Chil ; 147(6): 751-754, 2019 Jun.
Article de Espagnol | MEDLINE | ID: mdl-31859828

RÉSUMÉ

BACKGROUND: There are several types of primary malignant hepatic tumors (PMHT) other than hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC): they are infrequent and poorly known. Imaging studies could help characterize the lesions and may guide the diagnosis. However, the definitive diagnosis of PMHT is made by pathology. AIM: To review a registry of liver biopsies performed to diagnose hepatic tumors. PATIENTS AND METHODS: Review of a pathology registry of liver biopsies performed for the diagnosis of liver tumors. Among these, 25 patients aged 57 ± 17 years, 60% males, in whom a liver tumor other than a HCC or CC was diagnosed, were selected for review. The medical records of these patients were reviewed to register their clinical characteristics, imaging and the pathological diagnosis performed during surgery and/ or with the percutaneous liver biopsy. RESULTS: Ten patients (40%) had neuroendocrine tumors, six (24%) had a lymphoma and four (16%) had hepatic hemangioendothelioma. Angiosarcoma and sarcomatoid carcinoma were diagnosed in one patient each. In 22 patients (88%), neither clinical features nor imaging studies gave the correct diagnosis. Four patients (16%) had chronic liver disease. The most frequent symptoms were weight loss in 28% and abdominal pain in 24%. CONCLUSIONS: The most common PMHT other than HCC and CC were neuroendocrine tumors and lymphomas. Imaging or clinical features were not helpful to reach the correct diagnosis.


Sujet(s)
Carcinomes/épidémiologie , Hémangioendothéliome/épidémiologie , Tumeurs du foie/épidémiologie , Lymphomes/épidémiologie , Tumeurs neuroendocrines/épidémiologie , Sarcomes/épidémiologie , Adulte , Biopsie , Carcinomes/anatomopathologie , Chili/épidémiologie , Comorbidité , Femelle , Hémangioendothéliome/anatomopathologie , Humains , Tumeurs du foie/anatomopathologie , Lymphomes/anatomopathologie , Mâle , Adulte d'âge moyen , Tumeurs neuroendocrines/anatomopathologie , Prévalence , Études rétrospectives , Sarcomes/anatomopathologie
18.
Rev Chil Pediatr ; 90(3): 316-320, 2019 Jun.
Article de Espagnol | MEDLINE | ID: mdl-31344192

RÉSUMÉ

INTRODUCTION: Hepatic hemangioendothelioma is a rare benign tumor in children, which frequently occurs in the first year of life. The clinical presentation is variable and the diagnosis is based on clinical suspicion, and laboratory and imaging studies. The objective was to describe a case of multifocal hepa tic hemangioendothelioma. CLINICAL REPORT: 3-month-old girl who presented hepatomegaly without elements of hepatic or heart failure. Abdominal ultrasound and CT scan were used to diagnose hepatic hemangioendothelioma, which was confirmed by CT abdominal angiography. The patient received glucocorticoid treatment at high doses for a prolonged period. A year and a half after treatment, there was evidence of tumor remission. She had side effects from the established treatment. CONCLUSIONS: In asymptomatic patients with isolated hepatomegaly, it should be considered a probable tumor patho logy, considering the clinic and imaging studies. Possible complications and treatments risks must always be assessed. In this case, the tumor extension and its probable complications justified the use of prolonged corticosteroid therapy at high doses despite its adverse effects.


Sujet(s)
Hémangioendothéliome/imagerie diagnostique , Hépatomégalie/imagerie diagnostique , Tumeurs du foie/imagerie diagnostique , Angiographie par tomodensitométrie , Femelle , Glucocorticoïdes/administration et posologie , Hémangioendothéliome/traitement médicamenteux , Hépatomégalie/traitement médicamenteux , Hépatomégalie/étiologie , Humains , Nourrisson , Tumeurs du foie/traitement médicamenteux , Résultat thérapeutique , Échographie
19.
Rev. méd. Chile ; 147(6): 751-754, jun. 2019. tab
Article de Espagnol | LILACS | ID: biblio-1043157

RÉSUMÉ

Background: There are several types of primary malignant hepatic tumors (PMHT) other than hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC): they are infrequent and poorly known. Imaging studies could help characterize the lesions and may guide the diagnosis. However, the definitive diagnosis of PMHT is made by pathology. Aim: To review a registry of liver biopsies performed to diagnose hepatic tumors. Patients and Methods: Review of a pathology registry of liver biopsies performed for the diagnosis of liver tumors. Among these, 25 patients aged 57 ± 17 years, 60% males, in whom a liver tumor other than a HCC or CC was diagnosed, were selected for review. The medical records of these patients were reviewed to register their clinical characteristics, imaging and the pathological diagnosis performed during surgery and/ or with the percutaneous liver biopsy. Results: Ten patients (40%) had neuroendocrine tumors, six (24%) had a lymphoma and four (16%) had hepatic hemangioendothelioma. Angiosarcoma and sarcomatoid carcinoma were diagnosed in one patient each. In 22 patients (88%), neither clinical features nor imaging studies gave the correct diagnosis. Four patients (16%) had chronic liver disease. The most frequent symptoms were weight loss in 28% and abdominal pain in 24%. Conclusions: The most common PMHT other than HCC and CC were neuroendocrine tumors and lymphomas. Imaging or clinical features were not helpful to reach the correct diagnosis.


Sujet(s)
Humains , Mâle , Femelle , Adulte , Adulte d'âge moyen , Sarcomes/épidémiologie , Carcinomes/épidémiologie , Tumeurs neuroendocrines/épidémiologie , Hémangioendothéliome/épidémiologie , Tumeurs du foie/épidémiologie , Lymphomes/épidémiologie , Sarcomes/anatomopathologie , Biopsie , Carcinomes/anatomopathologie , Comorbidité , Chili/épidémiologie , Prévalence , Études rétrospectives , Tumeurs neuroendocrines/anatomopathologie , Hémangioendothéliome/anatomopathologie , Tumeurs du foie/anatomopathologie , Lymphomes/anatomopathologie
20.
Rev. chil. pediatr ; 90(3): 316-320, jun. 2019. graf
Article de Espagnol | LILACS, UY-BNMED, BNUY | ID: biblio-1013839

RÉSUMÉ

INTRODUCCIÓN: El hemangioendotelioma hepático (HEH) es un tumor benigno, raro en niños, que se presenta frecuentemente en el primer año de vida. La presentación clínica es variable y su diagnóstico se realiza en base a la sospecha clínica, estudios de laboratorio y de imagen. El objetivo fue describir un caso de hemangioendotelioma hepático multifocal. CASO CLÍNICO: Niña de 3 meses que presentó hepatomegalia sin elementos de falla hepática ni cardiaca. Se realizó ecografía y tomografía de ab domen que orientaron al diagnóstico de HEH que se confirmó con la angioresonancia de abdomen. Recibió glucocorticoides a altas dosis en forma prolongada. Al año y medio de iniciado el tratamiento se evidenció remisión del tumor. Presentó efectos secundarios por el tratamiento instaurado. CONCLUSIONES: La presencia de una hepatomegalia aislada en un lactante asintomático debe hacer pensar en una probable patología tumoral, orientándonos por la clínica e imagenología al diagnóstico nosológico de la misma. Siempre se debe sospesar las posibles complicaciones con los riesgos de los tratamientos a realizar. En este caso la extensión del tumor y sus probables complicaciones justificó el uso de corticoterapia prologada a altas dosis a pesar de sus efectos adversos.


INTRODUCTION: Hepatic hemangioendothelioma is a rare benign tumor in children, which frequently occurs in the first year of life. The clinical presentation is variable and the diagnosis is based on clinical suspicion, and laboratory and imaging studies. The objective was to describe a case of multifocal hepa tic hemangioendothelioma. CLINICAL REPORT: 3-month-old girl who presented hepatomegaly without elements of hepatic or heart failure. Abdominal ultrasound and CT scan were used to diagnose hepatic hemangioendothelioma, which was confirmed by CT abdominal angiography. The patient received glucocorticoid treatment at high doses for a prolonged period. A year and a half after treatment, there was evidence of tumor remission. She had side effects from the established treatment. CONCLUSIONS: In asymptomatic patients with isolated hepatomegaly, it should be considered a probable tumor patho logy, considering the clinic and imaging studies. Possible complications and treatments risks must always be assessed. In this case, the tumor extension and its probable complications justified the use of prolonged corticosteroid therapy at high doses despite its adverse effects.


Sujet(s)
Humains , Femelle , Nourrisson , Hémangioendothéliome/imagerie diagnostique , Hépatomégalie/imagerie diagnostique , Tumeurs du foie/imagerie diagnostique , Résultat thérapeutique , Angiographie par tomodensitométrie , Glucocorticoïdes/administration et posologie , Hémangioendothéliome/traitement médicamenteux , Hépatomégalie/étiologie , Hépatomégalie/traitement médicamenteux , Tumeurs du foie/traitement médicamenteux
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE